<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1A515510-3DD6-448D-B145-2D02C4D53A7D"><gtr:id>1A515510-3DD6-448D-B145-2D02C4D53A7D</gtr:id><gtr:name>Murdoch University</gtr:name><gtr:address><gtr:line1>Murdoch University</gtr:line1><gtr:line2>South Street</gtr:line2><gtr:postCode>6150</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1A515510-3DD6-448D-B145-2D02C4D53A7D"><gtr:id>1A515510-3DD6-448D-B145-2D02C4D53A7D</gtr:id><gtr:name>Murdoch University</gtr:name><gtr:address><gtr:line1>Murdoch University</gtr:line1><gtr:line2>South Street</gtr:line2><gtr:postCode>6150</gtr:postCode><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E89C5F6C-3EB1-417F-943E-127C327DAEDD"><gtr:id>E89C5F6C-3EB1-417F-943E-127C327DAEDD</gtr:id><gtr:firstName>Eleanor</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F601"><gtr:id>97C3A7E9-2462-479F-878C-E2488E8398B3</gtr:id><gtr:title>Defining protective immunity in hepatitis C virus infection, using novel ultra-sensitive techniques</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/601</gtr:grantReference><gtr:abstractText>Hepatitis C virus is a pandemic infection. Following infection with HCV the majority of individuals develop persistent infection associated with progressive liver disease and ultimately liver cirrhosis. The minority spontaneously eradicate the virus. The reasons as to why individuals have completely different clinical outcomes are currently unclear. 

The best therapy to date for HCV infection is interferon- given in combination with ribavirin over 6-12 months. This therapy is effective in 45% of patients with genotype-1 HCV infection, but in 75% of genotype-3 infection. In the UK the majority of individuals are infected with therapy resistant genotype-1 HCV infection. The reasons for the dramatically different response rates between viral genoptypes is not known. 

I plan to assess the role of the immune response, and in particular the T-lymphocyte response, in determining the resolution of HCV infection. I will assess this both in the context of spontaneous resolution and in the context of therapy. A better understanding of the factors which influence viral control is crucially important in directing future effective therapeutic and vaccination strategies.</gtr:abstractText><gtr:technicalSummary>Aims and relevance: Hepatitis C virus (HCV) infects 170 million people and is a significant cause of patient mortality and morbidity. My aim is to define those aspects of cellular immunity associated with viral control. This is essential for the development of future therapeutic strategies.

Scientific objectives and plan: My objectives are to study this in two distinct situations: (1) spontaneous control of virus following primary infection; (2) control of virus during drug therapy.
 Following primary infection, 15% of individuals spontaneously control virus, whilst 85% develop persistent infection. Once persistent infection is established T-cell responses are clearly attenuated. However, previous work has shown that the quality of the T-cell response as well as the magnitude of the response is likely to play an important role in determining outcome. I plan to determine the qualitative aspects of the T-cell response in individuals with distinct clinical outcomes and to track the evolution of these responses and the virus during the primary phase of infection. I have established a collaboration with Dr. Paolo Fabris (Italy) who is providing sequential samples from patients with primary HCV infection. 
 My second objective is to study the cellular immune responses associated with viral control during combination therapy (pegylated-interferon- and ribavirin), having previously demonstrated that these drugs have immunomodulatory activity, in vitro and in vivo. During combination therapy, a sustained virological response is achieved in only 45% of genotype-1 patients treated for 12 months, but in 75% of genotype-3 patients treated for 6 months. Despite this fascinating observation, the host cellular response to genotype-3 infection is currently completely unknown. Since the viral sequences of these genotypes are very different they will present distinct T-cell epitopes. Thus, one explanation is that there is a different T-cell response to genotype-3 infection, which is preferentially enhanced by combination therapy. I plan to examine this hypothesis.

Design and collaborations: This will involve the use of techniques that I am proficient in (ELISpot matrix of genotype specific peptides to define HCV epitopes, panels of HLA class-I and HLA class-II tetramers, the technique of magnetic selection to identify rare populations of HCV specific T-cells, phenotypic analysis, cytokine secretion and cytotoxicity assays). Additionally I will develop techniques that are new to me. To do this I have set up the following collaborations; E. Holmes (Oxford) and Peter Simmonds (Edinburgh) -the analysis of viral evolution, V. Cerundolo (IMM, Oxford)-T-cell priming, A. Sewell (Oxford)-TCR affinity binding.</gtr:technicalSummary><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>752059</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Zoology</gtr:department><gtr:description>Evolutionary analysis of HCV genotype-6 infection in Asia</gtr:description><gtr:id>3CF59090-5CC8-4F8B-9ECC-10C50FB356F7</gtr:id><gtr:impact>18971279</gtr:impact><gtr:outcomeId>86FE7FE865B-1</gtr:outcomeId><gtr:partnerContribution>The provision of expertise in phylogentic analysis</gtr:partnerContribution><gtr:piContribution>Genetic sequencing, sample collection and data analysis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>industry partner collaboration-Okairos</gtr:description><gtr:id>8DAAABD0-DDB1-4C83-AE68-2EF0B2B9745D</gtr:id><gtr:impact>This collaboration is essential to meet the aims of the project</gtr:impact><gtr:outcomeId>TEAn1nqjAqs-1</gtr:outcomeId><gtr:partnerContribution>production and supply of HCV adenoviral and MVA viral vectored vaccines</gtr:partnerContribution><gtr:piContribution>We have embarked on a HCV vaccine research program in healthy volunteers and HCV infected patients. We have designed three phase I clinical studies, are recruiting and caring for the patients, and are performing the immunology assays and data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Murdoch University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Centre for Clinical Immunology and Biomedical Statistics</gtr:department><gtr:description>Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia</gtr:description><gtr:id>DDEEA833-0033-457A-B7C2-CF02EA64F5F7</gtr:id><gtr:impact>19670417 19263475</gtr:impact><gtr:outcomeId>FCB1FDB4640-1</gtr:outcomeId><gtr:partnerContribution>This group performed HLA and sequence analysis on HCV samples to identify immune selective pressures in HCV infection.</gtr:partnerContribution><gtr:piContribution>We performed detailed sequence analysis in a cohort of HCV genotype-3 infected patients, performed data analysis and manuscript preparation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Biopharmaceutical company-Okairos</gtr:description><gtr:id>727F3421-F83B-4F40-BBFC-264529C72FC8</gtr:id><gtr:impact>Plenary session presentation at American liver meeting 2009. An MRC experimental medicine award to assess the same vaccine in HCV infected patients in an academic led study.</gtr:impact><gtr:outcomeId>9358A8AFAD4-1</gtr:outcomeId><gtr:partnerContribution>Okairos have made the adenoviral vaccine vectors required for our phase I clinical studies and have helped in project management</gtr:partnerContribution><gtr:piContribution>We have embarked on a HCV vaccine research program in healthy volunteers and HCV infected patients. We have designed three phase I clinical studies, are recruiting and caring for the patients, and are performing the immunology assays and data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public lecture series</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>6E3FFF58-25EB-49B0-8A83-4CE82694EEAD</gtr:id><gtr:impact>As Above

Further dissemination to the public resulted with an invitations to write for public news letters</gtr:impact><gtr:outcomeId>75E56F96C8D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture series to HCV infected patients</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D29AAFB6-9856-492C-856E-F4470A63AEE7</gtr:id><gtr:impact>50 patients and interested health care professionals attended.

Initial talk has turned into a 6 monthly rolling programme.</gtr:impact><gtr:outcomeId>A7ZRgXAH87e</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009,2010,2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>public lecture Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>F713134A-E09D-424F-84CB-C0C064949895</gtr:id><gtr:impact>40 patients and interested health care workers attended a public lecture (held every 6 months) which sparked questions, discussions and resulted in us recruiting lay people to our research group.

Resulted in patient recruitment to our study.</gtr:impact><gtr:outcomeId>JTv5R3j1V1e</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dissemination of information about Oxford HCV vaccine programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4321675E-B63C-4FEB-A2C9-7D6DBA4C8378</gtr:id><gtr:impact>We wrote an article (in press) that is distributed to both health professionals and patients about the HCV Oxford vaccine programme,

Publication-in press</gtr:impact><gtr:outcomeId>5B5C9159C0C</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Liver Congress, EASL 2017 (Barcelona)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>45C346EE-0A2E-417A-8E67-5DDD02D27066</gtr:id><gtr:impact>Registry grant presentation&amp;quot; Thursday 14 April 2016 from 12:00 to 13:30.</gtr:impact><gtr:outcomeId>58beb7994f8d82.34452957</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>News letter-viral hepatitis</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5B0E8C8C-8B89-4A85-B55C-B1194E9DE707</gtr:id><gtr:impact>This study was presented in a newsletter on viral hepatitis that is sent to healthcare professionals in Europe.

N/A</gtr:impact><gtr:outcomeId>ArvvkHZvdRq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>270000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Clinical Training Fellowship; Natural History and Pathogenesis of Systemic IgG4 Disease</gtr:description><gtr:end>2014-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>5FF69D6E-0586-40BD-8876-9BB552114CFC</gtr:id><gtr:outcomeId>ZJi7qoTjAft0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR Oxford Biomedical Research Centre-cohorts</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>E0590A19-3ECD-4A52-9955-FB76305B96CC</gtr:id><gtr:outcomeId>DE2E4C1AC400</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>208000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Biomedical Sciences Training Fellowship; Biological role of IFN-lambda-3</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8F251778-7C02-4769-AB7F-ADF0B757D667</gtr:id><gtr:outcomeId>n6mAM9RttcX0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>47000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NDM studentship award; T cell immunity to HCV gt3a infection</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00885DD4-5DBD-4C47-9626-324A9998008C</gtr:id><gtr:outcomeId>WCd8THCQz3c0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42870</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NDM studentship</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>782A72B3-A2E0-49FA-A52F-CD404A4CA371</gtr:id><gtr:outcomeId>kGrGoM9P5F60</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC senior fellowship</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>13CC8DF9-59CD-413F-A7F6-53AC0AE520E4</gtr:id><gtr:outcomeId>TGM46kTnVw7</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>94199</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Oxford Biomedical Research Centre</gtr:department><gtr:description>NIHR Oxford Biomedical Research Centre-FSF funding</gtr:description><gtr:end>2011-04-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>387D5A62-961B-4D78-A8FC-96FB2CBA6BD9</gtr:id><gtr:outcomeId>42CB20B39910</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>We have assessed a novel HCV vaccine in healthy volunteers we have shown to be safe and highly immunogenic.</gtr:description><gtr:id>05641B30-2C79-4268-BD3E-5BE35A62E280</gtr:id><gtr:impact>Further funding (MRC experimental medicine award) to assess the same vaccine in HCV infected patients has been obtained</gtr:impact><gtr:outcomeId>98434EE1DEC</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>An adenoviral vectored vaccine for HCV infection</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>HCV MVA viral vectored vaccine, in phase-I clinical studies, funded by Okairos and the MRC DCS award in collaboration.</gtr:description><gtr:id>FABD7BEC-7BA8-4BE6-AF25-1B4827781422</gtr:id><gtr:impact>Ni yet</gtr:impact><gtr:outcomeId>r9MypQo9tCr</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>MVA vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>MVA vector that contains the entire non-structural regions of the HCV polyprotein.</gtr:description><gtr:id>A8375C54-C546-4103-B6B5-78BB56BE75EA</gtr:id><gtr:impact>phase II efficacy study underway</gtr:impact><gtr:outcomeId>niAWWgebond</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MVA vectored HCV vaccine</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This is state of the art database that we instigated in 2009 to collect clinical information on HCV patients for a longitudinal cohort study of HCV. This will inform not only natural history, but also identify markers of HCV progression and aid recruittment of studies of experimental medicine.</gtr:description><gtr:id>B95C18EA-949B-4F91-881F-A33A30C27E2D</gtr:id><gtr:impact>No impacts yet, though this tool has been very recently conceived</gtr:impact><gtr:outcomeId>088C9019A13</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A state of the art Cellma HCV database to establish a HCV patient cohort</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>1405D7A8-7D28-42AF-AD5C-FFA421E7BF03</gtr:id><gtr:title>Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3ad4b8c9d783c62cc7546742e71420df"><gtr:id>3ad4b8c9d783c62cc7546742e71420df</gtr:id><gtr:otherNames>Humphreys I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>20A2AA78BDA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>090E65CB-A262-4B0A-B2CB-C6FC72D21EBF</gtr:id><gtr:title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e878b1af1aa4bdbd1966248e20dba0a"><gtr:id>1e878b1af1aa4bdbd1966248e20dba0a</gtr:id><gtr:otherNames>Colloca S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>hHFKPnBEXvE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378F54EC-72D4-4917-96D8-E9C30F2DA2D3</gtr:id><gtr:title>Genetic history of hepatitis C virus in East Asia.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/481c6c5b334649dd75673417a87f825b"><gtr:id>481c6c5b334649dd75673417a87f825b</gtr:id><gtr:otherNames>Pybus OG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>0B857D855D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD110D3F-59C8-40A9-94AB-3A2A270F4FAA</gtr:id><gtr:title>The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos.</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91a56318405fb93ae49f510bc330a30d"><gtr:id>91a56318405fb93ae49f510bc330a30d</gtr:id><gtr:otherNames>Syhavong B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn><gtr:outcomeId>56cf08e85d40c2.40351738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2BDD95F9-AB8D-4C77-8C2C-CC57A663FF0D</gtr:id><gtr:title>What are the prospects for controlling hepatitis C?</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d9125178bea693a9bb3eae81b908265"><gtr:id>7d9125178bea693a9bb3eae81b908265</gtr:id><gtr:otherNames>Klenerman P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>reYrSMFATNb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D392282A-631F-43D4-BBC5-7EB821805B62</gtr:id><gtr:title>Eight novel hepatitis C virus genomes reveal the changing taxonomic structure of genotype 6.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88cc0b3857e4454158c5b9ddf455220"><gtr:id>f88cc0b3857e4454158c5b9ddf455220</gtr:id><gtr:otherNames>Wang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_16395_25_23015745</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05907DA3-6147-49BD-9DCD-79267195395D</gtr:id><gtr:title>Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acad9a3b55b56611a7d851297c9f6445"><gtr:id>acad9a3b55b56611a7d851297c9f6445</gtr:id><gtr:otherNames>Neumann-Haefelin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>KpM6YuiUoUK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F80FDEF3-4D17-4FA5-B457-DE56361FB3FB</gtr:id><gtr:title>Virological footprint of CD4+ T-cell responses during chronic hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56638260fc01779765a581e06eaf22d1"><gtr:id>56638260fc01779765a581e06eaf22d1</gtr:id><gtr:otherNames>Fleming VM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>Bt2inXHfGbm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>779B76E8-FE47-4FF0-BD5A-FCA6E07D11CA</gtr:id><gtr:title>Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15677618d190f121dd682fd99401149d"><gtr:id>15677618d190f121dd682fd99401149d</gtr:id><gtr:otherNames>Billerbeck E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56cf08e8996498.12901251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5FC3053-9FD5-421B-A2E5-3C0C22647A8D</gtr:id><gtr:title>A rare cause of an ileocaecal mass and lymphadenopathy.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a50b7f86a652517d0cb7d1da4d96b549"><gtr:id>a50b7f86a652517d0cb7d1da4d96b549</gtr:id><gtr:otherNames>Culver EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56cf08e7f153f6.97582876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97AEADAD-3D36-4716-8621-3CF96A5F2832</gtr:id><gtr:title>Acute hepatitis C: clinical aspects, diagnosis, and outcome of acute HCV infection.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62faed74516470e576a6405e419c33e2"><gtr:id>62faed74516470e576a6405e419c33e2</gtr:id><gtr:otherNames>Fabris P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>22BFD004B1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>997E9785-A116-4BB7-9843-F5474B9B1B9E</gtr:id><gtr:title>Human MAIT and CD8aa cells develop from a pool of type-17 precommitted CD8+ T cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e010a90f68a03e6f502ca741eaf42f"><gtr:id>01e010a90f68a03e6f502ca741eaf42f</gtr:id><gtr:otherNames>Walker LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>tEg7MjpaUFd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ED764CD-12AE-4FE1-A302-CBA2A393547F</gtr:id><gtr:title>Vaccines in clinical trials: infectious disease.</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn><gtr:outcomeId>56cf08e82f4250.82077674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B467FB64-9965-494B-B300-E2CBCAFA65B9</gtr:id><gtr:title>Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>56cf09e5757178.24916588</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B5DCCCF-2413-47CC-B585-0513720D19C5</gtr:id><gtr:title>CD161(+)CD4(+) T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-?.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bf7d27c642565afc59f9dd9ee3dfc5b"><gtr:id>9bf7d27c642565afc59f9dd9ee3dfc5b</gtr:id><gtr:otherNames>Kang YH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_16395_25_23181064</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49F085F4-C74B-4F91-BBA4-28196A07D60A</gtr:id><gtr:title>Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4801377424f25fb15818390284aad8b7"><gtr:id>4801377424f25fb15818390284aad8b7</gtr:id><gtr:otherNames>Gaudieri S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>044AF585CCF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15A88B01-7BE8-42D1-AB9E-1F3719D46088</gtr:id><gtr:title>Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>ehYp9LbvqpM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02B04F2E-76D6-4680-9B6B-FB7196BE09C0</gtr:id><gtr:title>Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>060770D1C9E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51D48476-4260-469C-9D08-9C93BEED4B77</gtr:id><gtr:title>Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bea5f8959993c53cf1a585ba2b2a30ed"><gtr:id>bea5f8959993c53cf1a585ba2b2a30ed</gtr:id><gtr:otherNames>Rauch A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>A8F26569110</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDCA174E-3169-4A3C-BFD5-7107B7CE8E12</gtr:id><gtr:title>New approaches for biomarker discovery: the search for liver fibrosis markers in hepatitis C patients.</gtr:title><gtr:parentPublicationTitle>Journal of proteome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee8e47d5ca2ed34b98bf9e47c41be102"><gtr:id>ee8e47d5ca2ed34b98bf9e47c41be102</gtr:id><gtr:otherNames>Gangadharan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1535-3893</gtr:issn><gtr:outcomeId>avqjfZ38uce</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>67529D91-53DB-4F33-B21C-74AC194DA682</gtr:id><gtr:title>Discovery of novel biomarker candidates for liver fibrosis in hepatitis C patients: a preliminary study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee8e47d5ca2ed34b98bf9e47c41be102"><gtr:id>ee8e47d5ca2ed34b98bf9e47c41be102</gtr:id><gtr:otherNames>Gangadharan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16395_25_22761838</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4A51C35-058B-4102-8FD1-1768D7A41D32</gtr:id><gtr:title>Liver and Systemic Iron Loading Characterise Initial Disease Progression in Non-Alcoholic Fatty Liver Disease</gtr:title><gtr:parentPublicationTitle>Journal of Hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b61412769c5cf503a809c3adc79ed53"><gtr:id>5b61412769c5cf503a809c3adc79ed53</gtr:id><gtr:otherNames>Ryan J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bd74ce6b3701.77274384</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEE9346D-DE81-46F7-B2A1-8817511E5608</gtr:id><gtr:title>Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f91aeb7eb833fbdf35f914b8bd689722"><gtr:id>f91aeb7eb833fbdf35f914b8bd689722</gtr:id><gtr:otherNames>di Iulio J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>Dy7dV1UgUnc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F5D7C64-4AFD-4D8B-8C39-FD297E9979CD</gtr:id><gtr:title>HCV genotype-3a T cell immunity: specificity, function and impact of therapy.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6907a21c4983cd1a49f9edde1ba091df"><gtr:id>6907a21c4983cd1a49f9edde1ba091df</gtr:id><gtr:otherNames>Humphreys IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_16395_25_22337948</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/601</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>